Avtor/Urednik		Nalli, C; Andreoli, L; Motta, M; Norman, GL; Shums, Z; Binder, WL; Nuzzo, M; Frassi, M; Lojacono, A; Avčin, T
Naslov		La fine specificita degli anticorpi anti-beta2 glicoproteina I nelle malattie autoimmuni sistemiche e prevalentemente diretta verso il dominio 1
Prevedeni naslov		Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1
Tip		članek
Vir		Reumatismo
Vol. in št.		Letnik 63, št. 2
Leto izdaje		2011
Obseg		str. 91-6
Jezik		ita
Abstrakt		Objective: Anti-beta2 GPI are a formal laboratory criterion for the antiphospholipid syndrome (APS). They were demonstrated to be a risk factor for thrombosis and fetal losses but can also be detected in patients with systemic autoimmune disease (SAD), in healthy adults individuals and pre-school children. It has been suggested that different subpopulations of anti-beta2GPI may carry different pathogenetic potential: autoantibodies against Domain1 seem to be associated with thrombosis; autoantibodies against Domain4/5 have been identified in patients with non-thrombotic conditions. Methods: We studied 48 patients with SAD (32 systemic lupus erythematosus, 16 undifferentiated connettive tissue disease), 64 patients with APS, 57 one-year-old healthy children born to mother with SAD, 33 children with atopic dermatitis. All subjects were IgG anti-beta2 GPI positive. The specificity of anti-beta2 GPI was investigated using ELISA research products containing recombinant beta2 GPI D1 and D4/5 antigens. Cut-off values are calculated as 95th percentile on 100 NHD. IgG anti-beta2 GPI were tested at a validated home-made ELISA routinely performed in our laboratory. No thrombotic events were recordered in patients with SAD and in both groups of children. Results: Patients with SAD and APS showed prevalent reactivity for D1 while children in both groups preferentially recognize D4/5. Conclusions: IgG anti-beta2 GPI against D1 seem to cluster in patients with systemic autoimmune conditions. Their pathogenic potential in determine APS manifestations may be mitigated by adequate prophylaxis.
Deskriptorji		ANTIPHOSPHOLIPID SYNDROME ANTIBODIES, ANTIPHOSPHOLIPID THROMBOSIS AUTOANTIBODIES IGG LUPUS ERYTHEMATOSUS, SYSTEMIC DERMATITIS, ATOPIC ENZYME-LINKED IMMUNOSORBENT ASSAY GLYCOPROTEINS